Skip to Content

Investor Update

Basel, 17 March, 2008

Roche Science Event
Conference Call from ACC: HDL raising as a new therapeutic intervention and Roche’s CETP inhibitor R1658

We are pleased to invite you to a Conference Call discussing data on Roche’s CETP inhibitor R1658 presented at the American College of Cardiology meeting (ACC) in Chicago.

Date:Wednesday, 2nd April, 2008
  
Time:07.00 am to 08.00 am CDT (Chicago)
 02.00 pm to 03.00 pm CEST (Zurich)
 01.00 pm to 02.00 pm BST (London)
  
Speakers:Prof. Dr. Philip Barter, Director of the Heart Research Inst., Sydney, Australia
 Luke Miels, Strategic Marketing Head Metabolic Diseases, Roche
 Dr. Fouzia Laghrissi-Thode, Life Cycle Leader for R1658, Roche
 Dr. Karl Mahler, Head of Investor Relations, Roche
  
Program:- Background on HDL raising as a new therapeutic intervention
 - CETP inhibition: what is known so far
 - Safety data for Roche’s CETP inhibitor R1658 presented at ACC

The conference call will consist of a short presentation, followed by a Q&A session (with live access to the speakers).  

Analysts are invited to dial in to the conference call using the following dial-in numbers:

  • +41 (0) 91 610 56 00 (Europe)
  • +1 (1) 866 291 4166 (USA)  
  • +44 (0) 207 107 0611 (UK)  

Please dial in to the conference call 10 – 15 minutes before the call is scheduled to start.

Alternatively, a live audio webcast can be accessed via http://ir.roche.com (listen only, no access to speakers)

The presentation slides are available from the IR website at http://ir.roche.com.

A replay of the conference call will be available one hour after the conference call, for 48 hours.
Access is by dialling:

  • +41 (0) 91 612 43 30 (Europe)
  • +1 (1) 866 416 2558 (USA)  
  • +44 (0) 207 108 6233 (UK)  

Listeners will be asked to enter the ID 14708 followed by the # sign